AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.
AllStripes is currently partnering with more than 30 patient advocacy organizations across its 40 conditions, supporting more than 3,000 users to date. As a public benefit corporation (PBC), AllStripes is advocating for the importance of real-world evidence in development of treatments and is continuing to build tools that make research more inclusive for the global rare disease community.
In August 2021, the company raised a $50 million Series B funding round led by Lux Capital, and joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions (a Dassault Systèmes company), McKesson Ventures, and Maveron, along with angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation. The funding will support launching 100 new rare disease research programs.
AllStripes (formerly RDMD) was co-founded in 2017 by CEO Nancy Yu and Onno Faber, a rare disease patient deeply frustrated by the drug development process.
The name AllStripes was inspired by the official symbol for the rare disease community, the zebra.
- 90% covered medical, dental, & vision; 75% for dependents
- Paid Time Off + 14 paid holidays per year
- 12 weeks parental and family leave
- Life and disability insurance
- Cell and Internet reimbursement
- Team lunch and activities
- Home work setup budget
Updated August 27, 2021